Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor
BEIJING and SHANGHAI, China and BOSTON, MA, USA I May 2, 2021 I Jacobio Pharmaceuticals (1167.
Scientists' discovery of blood clotting mechanism could lead to new antithrombotic drugs
Scientists' discovery of blood clotting mechanism could lead to new antithrombotic drugs
For the first time, researchers have identified the specific mechanism of von Willebrand Factor (vWF)―an essential blood clotting protein―that enables it to bind to platelets and initiate ...
Moderna Invests To Make Up To 3 Billion More Covid Vaccines In 2022
Moderna Invests To Make Up To 3 Billion More Covid Vaccines In 2022
TOPLINE Biotech company Moderna announced it will increase its investment in Covid-19 vaccine manufacturing, enabling it to make up to 3 billion doses of its mRNA vaccine next year.
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
FLORHAM PARK, NJ, USA I April 29, 2021 I Phathom Pharmaceuticals, Inc.
BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
RESEARCH TRIANGLE PARK, NC, USA I April 30, 2021 IBioCryst Pharmaceuticals, Inc.
Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
NEW YORK, NY, USA I April 29, 2021 I Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, today announced the initiation...
World to spend $157 billion on COVID-19 vaccines through 2025 - report
World to spend $157 billion on COVID-19 vaccines through 2025 - report
(Reuters) - Total global spending on COVID-19 vaccines is projected to reach $157 billion by 2025, driven by mass vaccination programs underway and “booster shots” expected every two years...
Tris Pharma Announces Acquisition of Park Therapeutics - Pain Company with First-In-Class, Phase III-Ready New Chemical Entity (NCE)
Tris Pharma Announces Acquisition of Park Therapeutics - Pain Company with First-In-Class, Phase III-Ready New Chemical Entity (NCE)
MONMOUTH JUNCTION, N.
EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen
EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen
EMA has started evaluating an application to extend the use of Olumiant (baricitinib) to include treatment of COVID-19 in hospitalised patients from 10 years of age who require supplemental ox...
Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR, Surpasses 4.6 Billion Datapoints
Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR, Surpasses 4.6 Billion Datapoints
DALLAS, April 29, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ.
Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19
Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19
KENILWORTH, N.
Bayer confirms $200m Berkeley cell therapy facility
Bayer confirms $200m Berkeley cell therapy facility
The Cell Therapy Launch Facility will support Bayer’s growing advanced therapy ambitions and comes in addition to a $1.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand